What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
Mehmet Toner focuses on Microfluidics, Circulating tumor cell, Nanotechnology, Cell biology and Cancer.
His research investigates the link between Microfluidics and topics such as Gene expression that cross with problems in Regulation of gene expression.
His Circulating tumor cell study combines topics in areas such as Cancer cell, Cancer research, Prostate cancer and Pathology.
His studies in Cancer research integrate themes in fields like Wnt signaling pathway and Immunology.
He has included themes like DNA microarray, Cell, Cell culture and Hepatocyte in his Cell biology study.
His Cancer study incorporates themes from Molecular biology, Carcinoma and Antibody.
His most cited work include:
- Isolation of rare circulating tumour cells in cancer patients by microchip technology. (2800 citations)
- Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition (1552 citations)
- Detection of Mutations in EGFR in Circulating Lung-Cancer Cells (1397 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Microfluidics, Circulating tumor cell, Cell biology, Nanotechnology and Cryopreservation.
His studies deal with areas such as Whole blood and Biomedical engineering as well as Microfluidics.
His biological study spans a wide range of topics, including Cancer cell, Cancer research and Prostate cancer.
His Cancer research research incorporates themes from Breast cancer and Immunology.
His Cell biology research is multidisciplinary, incorporating perspectives in Cell, Cell culture and Hepatocyte.
His Cryopreservation research includes themes of Trehalose, Biochemistry, Oocyte and Andrology.
He most often published in these fields:
- Microfluidics (19.69%)
- Circulating tumor cell (18.12%)
- Cell biology (17.40%)
What were the highlights of his more recent work (between 2015-2021)?
- Circulating tumor cell (18.12%)
- Cancer research (12.27%)
- Cancer (9.70%)
In recent papers he was focusing on the following fields of study:
Circulating tumor cell, Cancer research, Cancer, Cryopreservation and Microfluidics are his primary areas of study.
His Circulating tumor cell study is focused on Metastasis in general.
His study looks at the intersection of Metastasis and topics like Cell with Machine perfusion.
His work carried out in the field of Cancer research brings together such families of science as RNA, Cell culture and Breast cancer.
He has researched Cancer in several fields, including Biopsy and Pathology.
His Microfluidics research is multidisciplinary, incorporating elements of Whole blood, Inertial frame of reference, Biophysics, Liquid biopsy and Biomedical engineering.
Between 2015 and 2021, his most popular works were:
- Clusters of circulating tumor cells traverse capillary-sized vessels (232 citations)
- Clusters of circulating tumor cells traverse capillary-sized vessels (232 citations)
- Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses (222 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Cancer
Mehmet Toner mostly deals with Circulating tumor cell, Cancer research, Metastasis, Microfluidics and Cell biology.
To a larger extent, Mehmet Toner studies Cancer with the aim of understanding Circulating tumor cell.
His Cancer research research incorporates elements of RNA, Breast cancer and Ribosomal protein.
The concepts of his Metastasis study are interwoven with issues in Cell, Cell culture and Immunology.
The Microfluidics study combines topics in areas such as Whole blood, Cell separation and Inertial frame of reference.
His work deals with themes such as Cancer cell, Supercooling, Liver preservation, Perfusion and Transplantation, which intersect with Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
